Mr. Rene Goehrum reports

BIOSYENT ANNOUNCES GRANT OF RESTRICTED SHARE UNITS

BioSyent Inc.'s board of directors has approved a grant of 66,020 restricted share units (RSUs) to certain directors, officers, management and employees of the company pursuant to the company's restricted share unit plan. These RSUs will fully vest within three years on the third anniversary of the applicable grant date.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol RX, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other health care products that have been successfully developed, are safe and effective, and have a proven record of improving the lives of patients. BioSyent supports the health care professionals that treat these patients by marketing its products through its community, specialty and international business units.

As of the date of this news release, the company has 11,616,492 common shares outstanding.

We seek Safe Harbor.